149 related articles for article (PubMed ID: 2861549)
1. Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease.
Case TC; Snider SR; Hruby VJ; Rockway T
Life Sci; 1985 Jul; 36(26):2531-7. PubMed ID: 2861549
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Xu DL; Yu WC; Pan GB; Chen SD
Adv Neurol; 1987; 45():587-90. PubMed ID: 2881450
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease].
Pan JB
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):205-8. PubMed ID: 2866940
[No Abstract] [Full Text] [Related]
4. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
Ott MC; Mishra RK; Johnson RL
Brain Res; 1996 Oct; 737(1-2):287-91. PubMed ID: 8930377
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man.
Barbeau A
Lancet; 1975 Oct; 2(7937):683-4. PubMed ID: 52054
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Fernandez HH; Odin P
Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
[TBL] [Abstract][Full Text] [Related]
7. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
[TBL] [Abstract][Full Text] [Related]
8. L-prolyl-L-leucyl-glycinamide analogues--a new class of peptide antihypertensives.
Rajakumar G; Singh AN; Naas F; Chiu S; Kwan CY; Johnson RL; Mishra RK
J Hypertens Suppl; 1986 Dec; 4(5):S106-8. PubMed ID: 2883271
[TBL] [Abstract][Full Text] [Related]
9. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
10. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
Gerschlager W; Bloem BR
Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
[No Abstract] [Full Text] [Related]
11. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Kask AM; Chase TN
J Neurol Neurosurg Psychiatry; 1987 Feb; 50(2):194-8. PubMed ID: 3572434
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide.
Chiu S; Mishra RK
Eur J Pharmacol; 1979 Jan; 53(2):119-25. PubMed ID: 32058
[TBL] [Abstract][Full Text] [Related]
13. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
14. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
15. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
16. Carbidopa/levodopa pharmacy errors in Parkinson's disease.
Khadem NR; Nirenberg MJ
Mov Disord; 2010 Dec; 25(16):2867-71. PubMed ID: 20818662
[TBL] [Abstract][Full Text] [Related]
17. Levodopa/carbidopa/entacapone in Parkinson's disease.
Seeberger LC; Hauser RA
Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
[TBL] [Abstract][Full Text] [Related]
18. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
[TBL] [Abstract][Full Text] [Related]
19. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
[TBL] [Abstract][Full Text] [Related]
20. [Levodopa medications in the treatment of Parkinson's disease].
Fedorova NV; Iablonskaia AIu; Bel'gusheva ME
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(5):30-6. PubMed ID: 21666590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
